Mikhail V. Blagosklonny
#111,493
Most Influential Person Now
Mikhail V. Blagosklonny's AcademicInfluence.com Rankings
Mikhail V. Blagosklonnyphilosophy Degrees
Philosophy
#4696
World Rank
#7312
Historical Rank
Logic
#2103
World Rank
#3018
Historical Rank
Mikhail V. Blagosklonnymathematics Degrees
Mathematics
#5477
World Rank
#7701
Historical Rank
Measure Theory
#750
World Rank
#1007
Historical Rank
Download Badge
Philosophy Mathematics
Why Is Mikhail V. Blagosklonny Influential?
(Suggest an Edit or Addition)Mikhail V. Blagosklonny's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 (2018) (3106)
- Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009 (2005) (2802)
- Classification of cell death: recommendations of the Nomenclature Committee on Cell Death (2005) (2403)
- Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012 (2011) (2295)
- Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes (2009) (2078)
- Stabilization of wild-type p53 by hypoxia-inducible factor 1α (1998) (859)
- Essential versus accessory aspects of cell death: recommendations of the NCCD 2015 (2014) (799)
- Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. (2002) (540)
- Disruption of the Raf-1-Hsp90 Molecular Complex Results in Destabilization of Raf-1 and Loss of Raf-1-Ras Association (*) (1995) (472)
- The Restriction Point of the Cell Cycle (2002) (424)
- Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. (1997) (422)
- Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. (1996) (397)
- Rapamycin decelerates cellular senescence (2009) (386)
- Molecular effects of paclitaxel: Myths and reality (a critical review) (1999) (364)
- p53 is associated with cellular microtubules and is transported to the nucleus by dynein (2000) (364)
- Aging: ROS or TOR (2008) (360)
- Growth stimulation leads to cellular senescence when the cell cycle is blocked (2008) (339)
- Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 (2018) (323)
- Aging and Immortality: Quasi-Programmed Senescence and Its Pharmacologic Inhibition (2006) (320)
- Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. (1996) (318)
- P21-dependent G 1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228 (2000) (311)
- Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice (2011) (308)
- p53 Inhibits Hypoxia-inducible Factor-stimulated Transcription* (1998) (300)
- The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway (2010) (281)
- Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway (1996) (280)
- Paradoxical suppression of cellular senescence by p53 (2010) (260)
- Antiangiogenic therapy and tumor progression. (2004) (244)
- Proteasome-dependent regulation of p21WAF1/CIP1 expression. (1996) (238)
- Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity (2001) (234)
- Rapamycin extends maximal lifespan in cancer-prone mice. (2010) (231)
- Mitotic Arrest and Cell Fate: Why and How Mitotic Inhibition of Transcription Drives Mutually Exclusive Events (2007) (226)
- Calorie restriction: Decelerating mTOR-driven aging from cells to organisms (including humans) (2010) (222)
- Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. (2002) (219)
- Taxol induction of p21WAF1 and p53 requires c-raf-1. (1995) (215)
- Growth and aging: a common molecular mechanism (2009) (214)
- The Regulation of Hypoxic Genes by Calcium Involves c-Jun/AP-1, Which Cooperates with Hypoxia-Inducible Factor 1 in Response to Hypoxia (2002) (211)
- Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics (2002) (210)
- Cell cycle arrest is not senescence (2011) (204)
- Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging (2012) (203)
- Pseudo-DNA damage response in senescent cells (2009) (197)
- Geldanamycin selectively destabilizes and conformationally alters mutated p53. (1995) (197)
- In vitro evaluation of a p53‐expressing adenovirus as an anti‐cancer drug (1996) (187)
- Carcinogenic metals induce hypoxia-inducible factor-stimulated transcription by reactive oxygen species-independent mechanism. (2000) (187)
- Answering the ultimate question “What is the Proximal Cause of Aging?” (2012) (177)
- p53 from complexity to simplicity: mutant p53 stabilization, gain‐of‐function, and dominant‐negative effect (2000) (172)
- Exploiting cancer cell cycling for selective protection of normal cells. (2001) (172)
- Bcl-xL is phosphorylated in malignant cells following microtubule disruption. (1998) (168)
- Carcinogenic nickel induces genes involved with hypoxic stress. (2000) (166)
- Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program (2010) (166)
- DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence (2010) (164)
- Cell senescence and hypermitogenic arrest (2003) (161)
- An anti-aging drug today: from senescence-promoting genes to anti-aging pill. (2007) (159)
- Hypoxia suppresses conversion from proliferative arrest to cellular senescence (2012) (159)
- P53: An ubiquitous target of anticancer drugs (2002) (158)
- Validation of anti-aging drugs by treating age-related diseases (2009) (149)
- Are p27 and p21 Cytoplasmic Oncoproteins? (2002) (143)
- Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture (2011) (141)
- Nickel-induced transformation shifts the balance between HIF-1 and p53 transcription factors. (1999) (138)
- Loss of function and p53 protein stabilization (1997) (137)
- Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo (1997) (135)
- Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/− mice (2012) (134)
- Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. (2003) (132)
- Weak p53 permits senescence during cell cycle arrest (2010) (130)
- Analysis of FDA Approved Anticancer Drugs Reveals the Future of Cancer Therapy (2004) (129)
- At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence (2009) (116)
- Flavopiridol, An Inhibitor of Transcription: Implications, Problems and Solutions (2004) (116)
- Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. (2000) (115)
- Flavopiridol Induces p53 via Initial Inhibition of Mdm2 and p21 and, Independently of p53, Sensitizes Apoptosis-Reluctant Cells to Tumor Necrosis Factor (2004) (115)
- Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program (2014) (112)
- Why Therapeutic Response May Not Prolong the Life of a Cancer Patient: Selection for Oncogenic Resistance (2005) (108)
- Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity (1997) (107)
- Oncogenic resistance to growth-limiting conditions (2002) (105)
- Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence (2009) (105)
- Rapamycin and quasi-programmed aging: Four years later (2010) (104)
- Geroconversion: irreversible step to cellular senescence (2014) (104)
- Matching targets for selective cancer therapy. (2003) (103)
- Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression (2011) (103)
- Cell senescence: Hypertrophic arrest beyond the restriction point (2006) (103)
- Prevention of cancer by inhibiting aging (2008) (103)
- Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. (2012) (102)
- TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists (2013) (102)
- Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. (1998) (101)
- New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53−/− mice by delaying carcinogenesis (2012) (101)
- Prospective treatment of age-related diseases by slowing down aging. (2012) (101)
- The interaction of p53 with replication protein A mediates suppression of homologous recombination (2004) (97)
- A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. (1999) (97)
- Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer. (2000) (96)
- Rapamycin for longevity: opinion article (2019) (96)
- Cancer stem cell and cancer stemloids: From biology to therapy (2007) (96)
- Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis (2008) (94)
- Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential (2009) (93)
- Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family (2002) (93)
- Conceptual biology: Unearthing the gems (2002) (90)
- Why men age faster but reproduce longer than women: mTOR and evolutionary perspectives (2010) (90)
- Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. (2005) (88)
- Molecular damage in cancer: an argument for mTOR-driven aging (2011) (88)
- Prospective strategies to enforce selectively cell death in cancer cells (2004) (87)
- From causes of aging to death from COVID-19 (2020) (87)
- Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). (2001) (87)
- TOR-driven aging: Speeding car without brakes (2009) (87)
- Cyclotherapy: Protection of Normal Cells and Unshielding of Cancer Cells (2002) (86)
- Suppression of replicative senescence by rapamycin in rodent embryonic cells (2012) (85)
- Paclitaxel Induces Primary and Postmitotic G1 Arrest in Human Arterial Smooth Muscle Cells (2004) (84)
- Tissue-selective therapy of cancer (2003) (82)
- Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells (2012) (82)
- Paradoxes of Aging (2007) (82)
- Hormesis does not make sense except in the light of TOR-driven aging (2011) (81)
- p21Waf1/Cip1/Sdi1 mediates retinoblastoma protein degradation (2007) (80)
- MEK drives cyclin D1 hyperelevation during geroconversion (2013) (78)
- Carcinogenesis, cancer therapy and chemoprevention (2005) (78)
- Overcoming limitations of natural anticancer drugs by combining with artificial agents. (2005) (78)
- The purpose of the HIF-1/PHD feedback loop: To limit mTOR-induced HIF-1α (2011) (77)
- Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection (2006) (77)
- Acute overexpression of wt p53 facilitates anticancer drug‐induced death of cancer and normal cells (1998) (75)
- Defects in p21WAF1/CIP1, Rb, and c-myc signaling in phorbol ester-resistant cancer cells. (1997) (74)
- Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to (2012) (74)
- Rapamycin extends life- and health span because it slows aging (2013) (73)
- How avastin potentiates chemotherapeutic drugs: Action and reaction in antiangiogenic therapy (2005) (73)
- Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21waf1/cip1 (1998) (72)
- Prevention of age-related macular degeneration-like retinopathy by rapamycin in rats. (2012) (72)
- CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence (2013) (71)
- Regulation of BRCA1 by protein degradation (1999) (70)
- Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer (2000) (69)
- Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet (2014) (69)
- From rapalogs to anti-aging formula (2017) (68)
- Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin (2014) (67)
- Aging, stem cells, and mammalian target of rapamycin: a prospect of pharmacologic rejuvenation of aging stem cells. (2008) (66)
- A node between proliferation, apoptosis, and growth arrest. (1999) (63)
- bcl-2 protein downregulation is not required for differentiation of multidrug resistant HL60 leukemia cells. (1996) (63)
- Molecular theory of cancer (2005) (63)
- Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs (2002) (62)
- Aging is not programmed (2013) (62)
- Linking calorie restriction to longevity through sirtuins and autophagy: any role for TOR (2010) (62)
- Accumulation of hypoxia-inducible factor-1α is limited by transcription-dependent depletion (2005) (60)
- Why human lifespan is rapidly increasing: solving "longevity riddle" with "revealed-slow-aging" hypothesis (2010) (60)
- Rapamycin-induced glucose intolerance: Hunger or starvation diabetes (2011) (60)
- Aging-suppressants: Cellular senescence (hyperactivation) and its pharmacologic deceleration (2009) (60)
- p21 (CDKN1A) is a Negative Regulator of p53 Stability (2007) (59)
- Teratogens as Anticancer Drugs (2005) (59)
- How Cancer Could be Cured by 2015 (2005) (59)
- Rapamycin suppresses brain aging in senescence-accelerated OXYS rats (2013) (59)
- Inhibition of Transcription Results in Accumulation of Wt p53 Followed by Delayed Outburst of p53-Inducible Proteins: p53 as a Sensor of Transcriptional Integrity (2002) (58)
- Cellular quiescence caused by the Mdm2 inhibitor Nutlin-3A (2009) (58)
- NCI's provocative questions on cancer: some answers to ignite discussion (2011) (57)
- Increasing healthy lifespan by suppressing aging in our lifetime: Preliminary proposal (2010) (57)
- Prolonged Mitosis Versus Tetraploid Checkpoint: How p53 Measures the Duration of Mitosis (2006) (56)
- Rapalogs in cancer prevention (2012) (55)
- Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program) (2015) (54)
- Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium (2014) (54)
- Targeting cancer cells by exploiting their resistance. (2003) (54)
- Cross-talk between protein kinase C-alpha (PKC-alpha) and -delta (PKC-delta): PKC-alpha elevates the PKC-delta protein level, altering its mRNA transcription and degradation. (1998) (54)
- Suppression of cancer cell growth by adenovirus expressing p21(WAF1/CIP1) deficient in PCNA interaction. (1996) (53)
- Apoptosis, proliferation, differentiation: in search of the order. (2003) (53)
- Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells. (2000) (52)
- Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation. (1998) (51)
- Paradox of Bcl-2 (and p53): why may apoptosis-regulating proteins be irrelevant to cell death? (2001) (48)
- Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging (2012) (47)
- Program‐like aging and mitochondria: Instead of random damage by free radicals (2007) (46)
- Progeria, rapamycin and normal aging: recent breakthrough (2011) (45)
- Gerosuppression by pan-mTOR inhibitors (2016) (45)
- Fasting and rapamycin: diabetes versus benevolent glucose intolerance (2019) (45)
- Resveratrol potentiates rapamycin to prevent hyperinsulinemia and obesity in male mice on high fat diet (2013) (45)
- Hypoxia, MTOR and autophagy (2013) (44)
- M(o)TOR of pseudo-hypoxic state in aging: Rapamycin to the rescue (2014) (44)
- Rapamycin, proliferation and geroconversion to senescence (2018) (44)
- Paclitaxel-Induced FasL-Independent Apoptosis and Slow (Non-Apoptotic) Cell Death (2002) (43)
- Selective anti-cancer agents as anti-aging drugs (2013) (42)
- Big mice die young but large animals live longer (2013) (42)
- Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression? (2012) (42)
- Why the disposable soma theory cannot explain why women live longer and why we age (2010) (41)
- Impact papers on aging in 2009 (2010) (40)
- Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin (2005) (40)
- MTOR-driven quasi-programmed aging as a disposable soma theory (2013) (39)
- Disease or not, aging is easily treatable (2018) (39)
- Cancer and aging: More puzzles, more promises? (2008) (39)
- Immunosuppressants in cancer prevention and therapy (2013) (38)
- Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions (2012) (38)
- Elimination of Proliferating Cells Unmasks the Shift from Senescence to Quiescence Caused by Rapamycin (2011) (38)
- How to save Medicare: the anti-aging remedy (2012) (38)
- UCN-01, a Protein Kinase C Inhibitor, Inhibits Endothelial Cell Proliferation and Angiogenic Hypoxic Response (1998) (38)
- The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. (2001) (38)
- “Targeting the absence” and therapeutic engineering for cancer therapy (2008) (38)
- The Histone Deacetylase Inhibitor FR901228 (Depsipeptide) Restores Expression and Function of Pseudo-Null p53 (2002) (37)
- The mitogen‐activated protein kinase pathway mediates growth arrest or E1A‐dependent apoptosis in SKBR3 human breast cancer cells (1998) (34)
- Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines. (2000) (34)
- Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint (2000) (34)
- Koschei the immortal and anti-aging drugs (2014) (34)
- Cell Immortality and Hallmarks of Cancer (2003) (33)
- Flavopiridol Inversely Affects p21WAF1/CIP1 and p53 and Protects p21-Sensitive Cells from Paclitaxel (2002) (33)
- Cytostatic and cytotoxic activity of sex steroids against human leukemia cell lines. (1994) (33)
- Aging: past, present and future (2009) (33)
- Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions. (2001) (32)
- Do VHL and HIF-1 mirror p53 and Mdm-2? Degradation-transactivation loops of oncoproteins and tumor suppressors (2001) (32)
- Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion (2014) (31)
- Cytostatic Activity of Paclitaxel in Coronary Artery Smooth Muscle Cells is Mediated Through Transient Mitotic Arrest Followed by Permanent Post-Mitotic Arrest: Comparison with Cancer Cells (2006) (30)
- Phosphorylation of paxillin tyrosines 31 and 118 controls polarization and motility of lymphoid cells and is PMA-sensitive (2004) (30)
- M(o)TOR of aging: MTOR as a universal molecular hypothalamus (2013) (29)
- A new science-business paradigm in anticancer drug development. (2003) (29)
- Dysregulation of the mTOR pathway in p53-deficient mice (2013) (28)
- Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines. (2001) (28)
- Hypoxia and gerosuppression: The mTOR saga continues (2012) (28)
- Rejuvenating immunity: “anti-aging drug today” eight years later (2015) (28)
- Inhibition of S6K by resveratrol: In search of the purpose (2009) (27)
- Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats (2015) (24)
- The power of chemotherapeutic engineering: Arresting cell cycle and suppressing senescence to protect from mitotic inhibitors (2011) (24)
- Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel. (2005) (24)
- S6K in geroconversion (2013) (24)
- Do cells need CDK2 and...Bcr-Abl? (2004) (23)
- Comparison of rapamycin schedules in mice on high-fat diet (2014) (22)
- Regulation of actin cytoskeleton in lymphocytes: PKC‐δ disrupts IL‐3–induced membrane ruffles downstream of Rac1 (1999) (21)
- Four Birds with One Stone: RAPA as Potential Anticancer (2002) (21)
- Fasting levels of hepatic p-S6 are increased in old mice (2014) (20)
- Re: Role of the heat shock response and molecular chaperones in oncogenesis and cell death. (2001) (20)
- Why Iressa Failed: Toward a Novel Use of Kinase Inhibitors (2003) (19)
- Antagonistic drug combinations that select against drug resistance: From bacteria to cancer (2007) (18)
- Flavopiridol Induces p 53 via Initial Inhibition of Mdm 2 and p 21 and , Independently of p 53 , Sensitizes Apoptosis-Reluctant Cells to Tumor Necrosis Factor (2004) (18)
- Does rapamycin slow down time? (2018) (17)
- Gefitinib (Iressa) in Oncogene-Addictive Cancers and Therapy for Common Cancers (2004) (16)
- Anti-aging: senolytics or gerostatics (unconventional view) (2021) (16)
- The hyperfunction theory of aging: three common misconceptions (2021) (16)
- Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells (2012) (15)
- How carcinogens (or telomere dysfunction) induce genetic instability: associated‐selection model (2001) (15)
- Why Iressa failed: toward novel use of kinase inhibitors (outlook). (2003) (14)
- The mystery of the ketogenic diet: benevolent pseudo-diabetes (2019) (13)
- Paradoxes of senolytics (2018) (12)
- Impact papers on aging in 2009 - eScholarship (2010) (11)
- Research by Retrieving Experiments (2007) (11)
- Gerosuppression in confluent cells (2014) (11)
- Metformin and sex: why suppression of aging may be harmful to young male mice (2010) (11)
- Cell senescence, rapamycin and hyperfunction theory of aging (2022) (11)
- Like p53, the proliferation-associated protein p120 accumulates in human cancer cells following exposure to anticancer drugs. (1998) (10)
- Depletion of Mutant p 53 and Cytotoxicity of Histone Deacetylase Inhibitors (2005) (10)
- Complementation of two mutant p53: Implications for loss of heterozygosity in cancer (2005) (10)
- Damage-induced aging and perpetual motion (2013) (9)
- While reinforcing cell cycle arrest, rapamycin and Torins suppress senescence in UVA-irradiated fibroblasts. (2017) (9)
- The hyperfunction theory: An emerging paradigm for the biology of aging Ageing Research Reviews (2021) (7)
- Strategies of Protection of Normal Cells During Chemo- and Radio-Therapy Based on Modulation of Cell Cycle and Apoptotic Pathways (2005) (7)
- The Second International Conference “Genetics of Aging and Longevity” (2012) (7)
- Advances in Brief Carcinogenic Metals Induce Hypoxia-inducible Factor-stimulated Transcription by Reactive Oxygen Species-independent Mechanism 1 (2000) (7)
- Librarians against scientists: Oncotarget’s lesson (2018) (6)
- Rapamycin for the aging skin (2019) (6)
- The goal of geroscience is life extension (2021) (6)
- Oligonucleotides protect cells from the cytotoxicity of several anti-cancer chemotherapeutic drugs. (1994) (6)
- DNA- and telomere-damage does not limit lifespan: evidence from rapamycin (2021) (6)
- Basic Cell Cycle and Cancer Research: Is Harmony Possible? (2002) (6)
- Hallmarks of cancer and hallmarks of aging (2022) (5)
- Hormonal and differentiation agents in cancer growth suppression. (2003) (5)
- Wild-type p53 marginally induces endogenous MDR-1 mRNA without causing a measurable drug resistance in human cancer cells. (2001) (5)
- Response to the thought-provoking critique of hyperfunction theory by Aubrey de Grey. (2021) (5)
- As predicted by hyperfunction theory, rapamycin treatment during development extends lifespan (2022) (4)
- No restriction points in life and science. (2002) (3)
- From the War on Cancer to Translational Oncology (2002) (3)
- The role of Bcl-2 protein and autocrine growth factors in a human follicular lymphoma-derived B cell line. (1995) (3)
- Cell Cycle Checkpoints and Cancer (2001) (3)
- Combining Phorbol Ester (PMA) with UCN-01: Fueling Fire with Water (2002) (2)
- Rapamycin, Inhibitor of Mtor Kinase, Sensitizes Leukemia Cells to Fludarabine-Induced Apoptosis, but Protects Survival of Normal Lymphocytes. (2004) (2)
- While reinforcing cell cycle arrest, rapamycin and Torins suppress senescence in UVA-irradiated fibroblasts (2017) (2)
- Conceptual Research and Phenomenology (2003) (2)
- A Phase II Study of High-Dose Tamoxifen in Patients with Hormone-refractory Prostate Cancer 1 (1999) (2)
- 2ME2 inhibits HIF-1 mRNA translation and its association with microtubules: Loss of microtubule-dependent HIF regulation in renal carcinoma cells (2005) (1)
- Rapamycin treatment early in life reprograms aging: hyperfunction theory and clinical practice (2022) (1)
- Mechanisms of Action of Cancer Chemotherapeutic Agents: Antimicrotubule Agents (2005) (1)
- Conceptual research and phenomenology--harmonizing slices. (2003) (1)
- Advances in Brief Hyperinducibility of Hypoxia-responsive Genes without p 53 / p 21-dependent Checkpoint in Aggressive Prostate Cancer 1 (2000) (1)
- Solving puzzles of aging: From disposable soma to signal-transduction pathways (2010) (1)
- Sensitive and simple bioassay for human tumour necrosis factor-alpha. (1993) (1)
- Spotlight on apoptosis. Introduction. (2000) (1)
- No limit to maximal lifespan in humans: how to beat a 122-year-old record (2021) (1)
- From Cytometry to Cell Cycle—A Portrait of Zbigniew Darzynkiewicz (2004) (0)
- Are menopause, aging and prostate cancer diseases? (2023) (0)
- Nuclear war on cancer (2002) (0)
- Cell Cycle Regulators as Targets of Anticancer Therapy (2003) (0)
- Apoptotic cell death in disease—Current understanding of the NCCD 2023 (2023) (0)
- As expected, based on rapamycin-like p53-mediated gerosuppression, mTOR inhibition acts as a checkpoint in p53-mediated tumor suppression (2022) (0)
- Cancer prevention with rapamycin (2023) (0)
- Impact papers on aging in 2009 Citation (2022) (0)
- Arthur B. Pardee: No Restriction Points in Life and Science (2002) (0)
- Altos Labs and the quest for immortality: but can we live longer right now? (2022) (0)
- Addendum: Librarians against scientists: Oncotarget’s lesson (2018) (0)
- Cellular senescence: when growth stimulation meets cell cycle arrest (2023) (0)
- Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells (2023) (0)
- From Cytometry to Cell Cycle (2004) (0)
- Introduction: Cycling from Oncology to Cardiology (2003) (0)
- What Are Programmed Theories of Aging (2012) (0)
- Referee acknowledgement for 2019 (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Mikhail V. Blagosklonny?
Mikhail V. Blagosklonny is affiliated with the following schools:
